Bryostatin 1

Generic Name: Bryostatin 1

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₆₈O_₁₇

CAS Number: 83314-01-6

Unique Ingredient Identifier: 37O2X55Y9E

Background: Bryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Safety of Bryostatin in Patients with MS

Phase 1

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Bryostatin 1

First Posted Date: 2024-01-05

Last Posted Date: 2024-11-04

Lead Sponsor: Robert Fox

Target Recruit Count: 20

Registration Number: NCT06190912

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Other: Placebo
Drug: Bryostatin 1

First Posted Date: 2020-09-03

Last Posted Date: 2024-07-31

Lead Sponsor: Neurotrope Bioscience, Inc.

Target Recruit Count: 122

Registration Number: NCT04538066

Locations: 🇺🇸
Fort Wayne Neurological Center, Fort Wayne, Indiana, United States
🇺🇸
Miami Dade Medical Research Institute, Miami, Florida, United States
🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States

and more 16 locations

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Other: Placebo
Drug: Bryostatin 1

First Posted Date: 2015-05-01

Last Posted Date: 2018-07-06

Lead Sponsor: Neurotrope Bioscience, Inc.

Target Recruit Count: 147

Registration Number: NCT02431468

Locations: 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸
J. Gary Booker, MD APMC Clinical Drug Trials, Shreveport, Louisiana, United States
🇺🇸
University of Kansas Alzheimer's Disease Center, Fairway, Kansas, United States

and more 26 locations

Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease

Phase 1

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Bryostatin 1

First Posted Date: 2014-08-21

Last Posted Date: 2017-11-06

Lead Sponsor: Neurotrope Bioscience, Inc.

Target Recruit Count: 9

Registration Number: NCT02221947

Locations: 🇺🇸
California Clinical Trials Medical Center, Glendale, California, United States

A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

First Posted Date: 2005-08-29

Last Posted Date: 2011-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00136461

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Recurrent Melanoma
Recurrent Renal Cell Cancer
Stage IV Melanoma
Stage IV Renal Cell Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: bryostatin 1
Drug: temsirolimus

First Posted Date: 2005-06-03

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00112476

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-08-13

Last Posted Date: 2013-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00003220

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States

Bryostatin 1 In Treating Patients With Progressive Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2004-08-09

Last Posted Date: 2013-06-26

Lead Sponsor: Cancer Research UK

Registration Number: NCT00005056

Locations: 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
🇬🇧
Imperial Cancer Research Fund Medical Oncology Unit, Oxford, England, United Kingdom

Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-07-26

Last Posted Date: 2014-04-11

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00003936

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2004-07-19

Last Posted Date: 2013-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00002908

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy